June 10, 2024
Americans’ interest in the potentially harmful “magic mushroom” Amanita muscaria is soaring, according to a new study. UC San Diego researchers suggest the market growth may be driven by clinical research on psilocybin’s safety and efficacy in treating depression.
May 3, 2017
Researchers at Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego mined the FDA Adverse Effect Reporting System 〈FAERS〉 database for depression symptoms in patients taking ketamine for pain. They found that depression was reported half as often among the more than 41,000 patients who took…
November 2, 2023
Psychedelic research has taken place at UC San Diego since the 1970s. But today, thanks to an interdisciplinary team from departments all across campus, that research has expanded to include human clinical trials exploring a range of treatments including chronic pain and mental health.
November 2, 2023
Psychedelic researchers are exploring psychedelics at all levels, from the cellular to the clinical, and in a range of fields and departments, from neuroscience and pain medicine to psychology and psychiatry.
June 28, 2024
Loosening local, state and federal regulations on cannabis and psychedelics has increased Americans’ interest in microdosing, according to a study from researchers at the University of California San Diego. Published in JAMA Health Forum, the study found that the rate of microdosing-related Google searches grew by 1250% from 2015 to…
